Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

NCT03261999 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Leuprolide Mesylate

Sponsor

Foresee Pharmaceuticals Co., Ltd.